Long-term treatment of multiple sclerosis with IgG immunotherapy

被引:0
|
作者
Schuller, E [1 ]
Lambin, P [1 ]
Deloche, G [1 ]
机构
[1] HOP LA PITIE SALPETRIERE,INTS,LAB IMMUNOCHEM,F-75651 PARIS 13,FRANCE
来源
PATHOLOGIE BIOLOGIE | 1996年 / 44卷 / 08期
关键词
multiple sclerosis; IgG therapy; long-term open trial;
D O I
暂无
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Thirty-five patients with a clinically [1] definite multiple sclerosis (M.S.) were treated in an open trial(1975 - 1993) with a standard dose preparation of total IgG (5 grams per week) by intra-muscular or intravenous injection. This treatment was used in 35 patients : during 3 to 16 years, Using Kurtzke's distability scale the results were : I) a significant deterioration (loss of 1 grade in the Kurtzke disability scale) only 14 years after the entry in the trial. 2) regarding current therapeutic results : improvement for 8 patients, deterioration fur 18, and stability for 9. Neither ?he age at the M.S. onset and at the entry, nor the duration of the disease, nor the disability score at the entry were factors modifying significantly the efficacy of the treatment. The comparison of these results with previous predictive studies (Confavreux, Weinshenker) suggests a significant reduction of M.S. progression, with an increase of-the functional independence period, No side-effects were observed and this immunotherapy, which may be convenient for home care. must be tested in properly controlled trials.
引用
收藏
页码:710 / 715
页数:6
相关论文
共 50 条
  • [41] The importance of long-term data in multiple sclerosis
    Montalban, Xavier
    JOURNAL OF NEUROLOGY, 2006, 253 (Suppl 6) : 9 - 15
  • [42] Long-term unmet needs in multiple sclerosis
    Moore, H. L. J.
    Abu Baker, A. M.
    Baster, K.
    Hobson, E.
    Paling, D.
    Sharrack, B.
    Nair, K. P. S.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 722 - 723
  • [43] Long-term ocrelizumab in progressive multiple sclerosis
    Rose, Deja R.
    Cohen, Jeffrey A.
    LANCET NEUROLOGY, 2020, 19 (12): : 966 - 968
  • [44] Long-term Survival in Multiple Sclerosis is Improving
    Wergeland, Stig
    Mannseth, Janne
    Atula, Sari
    Forsberg, Lars
    Glaser, Anna
    Joensen, Hanna
    Magyari, Melinda
    Soilu-Hanninen, Merja
    Viitala, Matias
    Hillert, Jan
    Grytten, Nina
    NEUROLOGY, 2023, 100 (17)
  • [45] Newer long-term treatments for multiple sclerosis
    Pryse-Phillips, W
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2002, 104 (03) : 265 - 271
  • [46] The importance of long-term data in multiple sclerosis
    Xavier Montalban
    Journal of Neurology, 2006, 253 : vi9 - vi15
  • [47] Long-term effects of childbirth in multiple sclerosis
    D'hooghe, M. B.
    Nagels, G.
    MULTIPLE SCLEROSIS, 2006, 12 : S131 - S131
  • [48] Long-term prognosis of multiple sclerosis in Australia
    McLeod, J. G.
    Barnett, M. H.
    Macaskill, P.
    Williams, D. B.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2007, 256 (1-2) : 35 - 38
  • [49] Natalizumab in Multiple Sclerosis: Long-Term Management
    Clerico, Marinella
    Artusi, Carlo Alberto
    Di Liberto, Alessandra
    Rolla, Simona
    Bardina, Valentina
    Barbero, Pierangelo
    De Mercanti, Stefania Federica
    Durelli, Luca
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (05)
  • [50] Progression in multiple sclerosis - a long-term problem
    Bittner, Stefan
    Zipp, Frauke
    CURRENT OPINION IN NEUROLOGY, 2022, 35 (03) : 293 - 298